AquaVac PD3
Active substance
ATC code
Species
Atlantic salmon (Salmo salar L).
Indications
For active immunisation of Atlantic salmon to reduce clinical signs (heart lesions and pancreas lesions), viremia, viral shedding and mortality from infection with SPDV (Pancreas disease) and to reduce mortality from infections with IPNV (Infectious pancreatic necrosis) and Aeromonas salmonicida subsp. salmonicida (furunculosis).
Onset of immunity: 500 degree days after vaccination for SPDV and Aeromonas salmonicida and 540 degree days after vaccination for IPNV.
Duration of immunity: demonstrated at 15 months post vaccination for SPDV and at 16 months post vaccination for Aeromonas salmonicida. Protection against mortality due to IPNV infection has been demonstrated at 4 months post vaccination in the field.
Dose to be administered and administration route
Dose: a single dose of 0.1 ml.
Administration: intraperitoneally along the central line, approximately 1 pelvic fin length in front of the pelvic fin base in Atlantic salmon. Shake the bottle well before use.
Vaccination is recommended for fish above 30 grams.
Food should be withheld for sufficient time (at least 48 hours) to ensure emptying of the gut prior to vaccination. The fish should be anaesthetised before vaccination. The length and the diameter of the applied needle should be adapted to the actual fish size. Ensure that the recommended dose is deposited into the abdominal cavity before the needle is withdrawn.
Adverse reactions
After vaccination melanisation and vaccine residues are very commonly observed in the abdominal cavity. Visceral adhesion may be observed; during the fresh water phase up to sea transfer phase slight to moderate adhesions (corresponding to Speilberg scores 1 – 3) very commonly occur while the occurrence of major adhesions (corresponding to Speilberg score of 4) is uncommon.
During the sea water phase mild adhesions (corresponding to Speilberg scores 1 – 2) are very common and moderate adhesions (corresponding to Speilberg score 3) are common.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
